Pharming Group (NASDAQ:PHAR) Earns “Buy” Rating from HC Wainwright

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $37.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 315.54% from the stock’s previous close.

PHAR has been the topic of a number of other research reports. Oppenheimer boosted their target price on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th. Jefferies Financial Group initiated coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.

Pharming Group Price Performance

Shares of NASDAQ:PHAR opened at $8.90 on Thursday. The company has a 50 day moving average of $8.90 and a 200 day moving average of $8.61. Pharming Group has a 12 month low of $6.65 and a 12 month high of $11.30. The stock has a market cap of $605.75 million, a P/E ratio of -34.25 and a beta of -0.10. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The business had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, sell-side analysts forecast that Pharming Group will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.